
1. j infect dis. 2015 sep 1;212(5):694-701. doi: 10.1093/infdis/jiv078. epub 2015
feb 11.

persistence sulfadoxine-pyrimethamine resistance despite reduction drug
pressure malawi.

artimovich e(1), schneider k(2), taylor te(3), kublin jg(4), dzinjalamala fk(5), 
escalante aa(6), plowe cv(1), laufer mk(1), takala-harrison s(1).

author information: 
(1)howard hughes medical institute/center vaccine development, university 
maryland school medicine, baltimore.
(2)department fakultät mathematik/naturwissenschaften/informatik, university
of applied sciences mittweida, germany.
(3)blantyre malaria project.
(4)fred hutchinson cancer research center, seattle, washington.
(5)department pharmacy, university malawi college medicine, blantyre.
(6)school life sciences, arizona state university, tempe.

background: 2007, malawi replaced sulfadoxine-pyrimethamine (sp) an
artemisinin-based combination therapy first-line treatment for
uncomplicated plasmodium falciparum malaria response failing sp efficacy.
here estimate effect reduced sp pressure prevalence of
sp-resistant parasites characteristics associated selective sweeps
flanking resistance loci.
methods: samples obtained individuals clinical malaria period 
of high sp use (1999-2001), transitional period (2007-2008), period of
low sp use (2012) genotyped resistance markers pfdhfr-ts codons 51,
59, 108 pfdhps codons 437, 540, 581. expected heterozygosity was
estimated evaluate genetic diversity flanking pfdhfr-ts pfdhps.
results: increase prevalence resistance haplotypes dhfr
51i/59r/108n dhps 437g/540e occurred sustained drug pressure, no
change haplotype prevalence 5 years reduction sp pressure. dhps
437g/540e/581g haplotype observed 2007 increased prevalence 
a period reduced sp pressure. changes sweep characteristics flanking
pfdhfr-ts pfdhps minimal.
conclusions: contrast rapid complete return of
chloroquine-susceptible falciparum malaria chloroquine withdrawn from
malawi, reemergence sp efficacy unlikely near future.

© author 2015. published oxford university press behalf the
infectious diseases society america. rights reserved. permissions,
please e-mail: journals.permissions@oup.com.

doi: 10.1093/infdis/jiv078 
pmcid: pmc4539899
pmid: 25672905  [indexed medline]

